Ramucirumab is a fully human monoclonal antibody (igg1) developed for the treatment of solid tumors.it is directed against the vascular endothelial growth factor receptor 2 (vegfr2). by binding to vegfr2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (vegf) to vegfr2. vegfr2 is known to mediate the majority of the downstream effects of vegf in angiogenesis.
المزيد من التفاصيل